City Holding Co’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

City Holding Co’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-235	Closed	-$4.28K	–	469
2024 Q2	$4.28K	Sell	235 -165	-41%	-$3.02K	﹤0.01%	424
2024 Q1	$7.36K	Hold	400	–	–	﹤0.01%	424
2023 Q4	$7.82K	Hold	400	–	–	﹤0.01%	423
2023 Q3	$7.16K	Hold	400	–	–	﹤0.01%	432
2023 Q2	$8.24K	Hold	400	–	–	﹤0.01%	432
2023 Q1	$8.18K	Hold	400	–	–	﹤0.01%	446
2022 Q4	$8.95K	Hold	400	–	–	﹤0.01%	440
2022 Q3	$8K	Hold	400	–	–	﹤0.01%	448
2022 Q2	$9K	Hold	400	–	–	﹤0.01%	428
2022 Q1	$11K	Hold	400	–	–	﹤0.01%	437
2021 Q4	$11K	Buy	+400	New	+$15K	﹤0.01%	436

Other funds holding GERM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

City Holding Co's GERM Position: Q3 2024 in Review

City Holding Co sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 235 shares — an estimated $4.28K sold.

City Holding Co first reported a position in GERM in Q4 2021 and held it in 11 quarters. The position peaked at $11K in Q1 2022. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.

City Holding Co reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
City Holding Co sold 235 Amplify Treatments, Testing and Advancements ETF shares in Q3 2024, an estimated $4.28K.
City Holding Co first reported a position in Amplify Treatments, Testing and Advancements ETF in Q4 2021 and held it in 11 quarters.
City Holding Co's Amplify Treatments, Testing and Advancements ETF position peaked at $11K in Q1 2022.
1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.

Based on City Holding Co's 13F filing for Q3 2024, filed 8 Oct 2024.